Managing drug resistance in cancer: lessons from HIV therapy (Q57340028)

The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic

21 January 2018

1 reference

21 January 2018

1 reference

Surrogate Endpoints And FDA’s Accelerated Approval Process

21 January 2018

1 reference

Changes in the HIV-1 mutational profile before first-line HAART in the RESINA cohort.

21 January 2018

1 reference

Transmission of drug-resistant HIV-1 in Europe remains limited to single classes

21 January 2018

1 reference

Outwitting evolution: fighting drug-resistant TB, malaria, and HIV.

21 January 2018

1 reference

Production of resistant HIV mutants during antiretroviral therapy

21 January 2018

1 reference

The use of human immunodeficiency virus resistance tests in clinical practice.

21 January 2018

1 reference

Comparison of HIV-1 genotypic resistance test interpretation systems in predicting virological outcomes over time

21 January 2018

1 reference

European guidelines on the clinical management of HIV-1 tropism testing

21 January 2018

1 reference

Selecting anti-HIV therapies based on a variety of genomic and clinical factors

21 January 2018

1 reference

Predicting the response to combination antiretroviral therapy: retrospective validation of geno2pheno-THEO on a large clinical database.

21 January 2018

1 reference

Bioinformatical assistance of selecting anti-HIV therapies: where do we stand?

21 January 2018

1 reference

Converting cancer therapies into cures: lessons from infectious diseases

21 January 2018

1 reference

A history of cancer chemotherapy

21 January 2018

1 reference

An overview of cancer multidrug resistance: a still unsolved problem

21 January 2018

1 reference

Strategies for optimizing combinations of molecularly targeted anticancer agents

21 January 2018

1 reference

Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements

21 January 2018

1 reference

Personalized medicine in oncology: the future is now.

21 January 2018

1 reference

Opportunities and challenges in the development of experimental drug combinations for cancer

21 January 2018

1 reference

Targeted agents: the rules of combination

21 January 2018

1 reference

Translating insights from the cancer genome into clinical practice

21 January 2018

1 reference

21 January 2018

Targeted cancer therapy

1 reference

Molecular predictors of response to trastuzumab and lapatinib in breast cancer.

21 January 2018

1 reference

Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy

21 January 2018

1 reference

Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer

21 January 2018

1 reference

Genomic approaches to lung cancer

21 January 2018

1 reference

From genes to drugs: targeted strategies for melanoma

21 January 2018

1 reference

New strategies in HER2-overexpressing breast cancer: many combinations of targeted drugs available

21 January 2018

1 reference

Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia

21 January 2018

1 reference

Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights

21 January 2018

1 reference

CYP2D6 and tamoxifen: DNA matters in breast cancer

21 January 2018

1 reference

Understanding resistance to EGFR inhibitors-impact on future treatment strategies

21 January 2018

1 reference

Diagnostics and biomarker development: priming the pipeline

21 January 2018

1 reference

Tumour stem cells and drug resistance

21 January 2018

1 reference

Preclinical modeling of combination treatments: fantasy or requirement?

21 January 2018

1 reference

Chemotherapy sensitivity and resistance assays: a systematic review

21 January 2018

1 reference

Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy

21 January 2018

1 reference

A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer

21 January 2018

1 reference

Sequencing technologies - the next generation

21 January 2018

1 reference

Cell type-specific gene expression differences in complex tissues

21 January 2018

1 reference

A pharmacogenomic method for individualized prediction of drug sensitivity

21 January 2018

1 reference

Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease

21 January 2018

1 reference

Discovery and preclinical validation of drug indications using compendia of public gene expression data

21 January 2018

1 reference

A DNA methylation fingerprint of 1628 human samples

21 January 2018

1 reference

Reference Maps of human ES and iPS cell variation enable high-throughput characterization of pluripotent cell lines

21 January 2018

1 reference

A change of strategy in the war on cancer.

21 January 2018

1 reference

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds

21 January 2018

1 reference

A network view of disease and compound screening

21 January 2018

1 reference

The cancer biomarker problem

21 January 2018

1 reference

21 January 2018

Of cancer and cave fish

1 reference

The endophenotype concept in psychiatry: etymology and strategic intentions

21 January 2018

1 reference

Psychiatric genetics: progress amid controversy

21 January 2018

1 reference

Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype

21 January 2018

1 reference

Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells

21 January 2018

1 reference

National marrow donor program HLA matching guidelines for unrelated adult donor hematopoietic cell transplants

21 January 2018

1 reference

Predicting cellular growth from gene expression signatures

21 January 2018

1 reference

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers

21 January 2018

1 reference

Computational methods for the design of effective therapies against drug resistant HIV strains

21 January 2018

1 reference

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

21 January 2018

1 reference

Systematic identification of genomic markers of drug sensitivity in cancer cells

21 January 2018

1 reference

Deploying whole genome sequencing in clinical practice and public health: meeting the challenge one bin at a time

21 January 2018

1 reference

21 January 2018

1 reference

Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure

31 March 2020

1 reference

Bioinformatics-assisted anti-HIV therapy

31 March 2020

1 reference

Cancer genomics: from discovery science to personalized medicine

31 March 2020

1 reference

A blueprint for advancing genetics-based cancer therapy

31 March 2020

1 reference

Tamoxifen in the treatment of breast cancer

31 March 2020

1 reference

Next-generation genomics: an integrative approach

31 March 2020

1 reference

31 March 2020

1 reference

Antiretroviral salvage therapy for multiclass drug-resistant HIV-1-infected patients: from clinical trials to daily clinical practice

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22673150

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Update of the drug resistance mutations in HIV-1: December 2010.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22673150

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

European recommendations for the clinical use of HIV drug resistance testing: 2011 update.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22673150